시장보고서
상품코드
1796158

미국의 처방상 장벽 : 조현병

Rx Barriers (US) - Schizophrenia

발행일: | 리서치사: FirstWord Group | 페이지 정보: 영문 | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

이 보고서는 조현병 시장에서 외부 장벽이 처방 결정에 어떤 영향을 미치는지 조사하고, 치료 의사들을 대상으로 한 설문조사 데이터를 바탕으로 비용, 가용성, 상환, 가이드라인, 환자 선호도 등의 요인이 치료 선택에 미치는 영향을 분석합니다. 조사 결과는 특정 브랜드를 처방하는 의사와 처방하지 않는 의사의 실태, 장벽이 처방 패턴을 어떻게 형성하는지, 경쟁 치료제 간 시장 점유율 변동에 대한 자세한 내용을 담고 있습니다.

주요 검토 과제:

  • 1.비용, 가용성, 환자 선호도와 같은 외부 요인이 브랜드 시장 점유율에 어떤 영향을 미치고 있는가?
  • 2.누가 브랜드 의약품을 처방하는지, 누가 처방하지 않는지, 어떤 의사가 처방을 검토할 의향이 있는가?
  • 3.의사는 어떻게 치료제를 선택하고, 어떤 장벽이 그 결정에 큰 영향을 미치는가?
  • 4.각 브랜드는 각종 장벽으로 인해 시장 점유율을 어느 정도 획득 또는 상실하고 있는가? 그리고 주요 경쟁자는 누구인가?

주요 브랜드

  • Abilify(aripiprazole)
  • Abilify Asimtufii(aripiprazole)
  • Abilify Maintena(aripiprazole)
  • Caplyta(lumateperone)
  • Clozaril(clozapine)
  • Cobenfy(trospium chloride/xanomeline)
  • Invega(paliperidone)
  • Invega Sustenna(paliperidone palmitate)
  • Latuda(lurasidone)
  • Lybalvi(olanzapine/samidorphan)
  • Risperdal(risperidone)
  • Vraylar(cariprazine)
  • Zyprexa(olanzapine)
KSA 25.09.01

This report examines how external market barriers influence prescribing decisions in the schizophrenia market. Drawing on survey data from treating physicians, it analyzes factors such as cost, availability, reimbursement, guidelines, and patient preferences, and their impact on therapy choice. The findings provide a detailed view of who is and is not prescribing specific brands, how barriers shape prescription patterns, and the resulting shifts in market share between competing therapies.

Key Questions Answered:

  • 1. How are external factors such as cost, availability, and patient preferences impacting your brand's market share?
  • 2. Who is and isn't prescribing your brand, and which physicians are willing to consider it?
  • 3. How do physicians choose therapies and which barriers significantly influence their decisions?
  • 4. How much market share does your brand gain or lose due to various barriers and who are the key competitors?

Key Brands:

  • Abilify (aripiprazole)
  • Abilify Asimtufii (aripiprazole)
  • Abilify Maintena (aripiprazole)
  • Caplyta (lumateperone)
  • Clozaril (clozapine)
  • Cobenfy (trospium chloride/xanomeline)
  • Invega (paliperidone)
  • Invega Sustenna (paliperidone palmitate)
  • Latuda (lurasidone)
  • Lybalvi (olanzapine/samidorphan)
  • Risperdal (risperidone)
  • Vraylar (cariprazine)
  • Zyprexa (olanzapine)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제